The Female Microbiome in Patients Undergoing Bladder Instillation Therapy

Status Active, not recruiting

Clinical Trial Summary

The underlying pathophysiology for BPS/IC is currently an active area of research. There is speculation that there may be alteration in the bladder and vaginal microbiome that contributes to the symptomatology of BPS/IC, however existing literature is limited and contradictory. Nickel et al (2015) studied the bladder microbiota in women with IC/BPS during a flare versus nonflare. The study collected initial stream and midstream urine specimens and detected overall, there was no significant differences in the species composition. However, a greater prevalence of fungi (Candida and Saccharomyces) was seen in the flare group (15.7%) versus the non-flare group (3.9%) midstream urine specimens. Pearce et al (2015) sought to characterize the urinary microbiome via catheterized specimens from women with urgency urinary incontinence, a condition that can present similarly as IC/BPS. The study found that more than half of the patients were sequence positive, most commonly for Lactobacillus (45%) or Gardnerella (17%), with 25% made up of various other bacteria. In contrast, Abernethy et al (2017) showed via catheterized urine specimens from patients with IC/BPS that the urinary microbiome is less diverse and less likely to contain Lactobacillus species. There have been two recent studies investigating the female urinary microbiome in patients with IC/BPS. Nickel et al (2019) found no differences in species composition between urine from patients with IC/BPS versus controls. Meriwether et al (2019) reported similar findings, and additionally found no differences when comparing the vaginal bacterial microbiome in patients with IC/BPS versus controls. However, in evaluating the bladder microbiome, both studies utilized uncatheterized urine specimens. Wolfe et al (2012) showed microbiome differences between clean-catch and catheterized urine specimens, therefore vaginal contamination in both studies cannot be ruled out.

Clinical Trial Description

This study uses samples collected under an interventional study and consented for use in future research - this study is use of those samples under the future research provision, and this study was deemed to meet exempt category 4. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05414305
Study type	Interventional
Source	Walter Reed National Military Medical Center
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	October 1, 2020
Completion date	December 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05414994` - Assessment of the Ocular Microbiome in Health and Disease
Completed	`NCT04769882` - Er:YAG Laser Effects on Microbial Population in Conservative Dentistry	N/A
Completed	`NCT04766528` - Effect of Diet on the Microbiota / Endoccanabinoidome Axis in Response to Physical Activity	N/A
Completed	`NCT03720314` - Microbiota Profiling in IBS
Completed	`NCT04122612` - Shaping Microbiome in the First 1,000 Days of Life
Not yet recruiting	`NCT05405634` - Microbiota in Chronic Anal Fissure and Its Association With Prognosis
Not yet recruiting	`NCT04895774` - Ex Vivo Study of the Mechanism of Action of Active Ingredients on the Intestinal Microbiota
Recruiting	`NCT05992688` - The Sweet Kids Study (Stevia on Weight and Energy Effect Over Time)	N/A
Recruiting	`NCT05502380` - Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery	Phase 3
Completed	`NCT05175833` - Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19	Phase 2
Recruiting	`NCT04836910` - Microbiome and Polycystic Ovaries
Recruiting	`NCT05603650` - Effects of Mouthrinses on the Microbiome of the Oral Cavity and GI Tract	N/A
Completed	`NCT04991818` - MSC - OneBiome UX Pilot Study	N/A
Completed	`NCT05575050` - Impact of Teeth Brushing in Ventilated COVID-19 Patients.	N/A
Completed	`NCT04374955` - The Effect of Probiotic Added to Maternal Diet on Infantile Colic and Intestinal Microbiota Content	N/A
Recruiting	`NCT04140747` - Transfer of Strictly Anaerobe Microbes From Mother to Child
Recruiting	`NCT04111471` - The Use of A Prebiotic to Promote a Healthy Gut Microbiome in Pediatric Stem Cell Transplant Recipients	N/A
Suspended	`NCT03220282` - The Milk, Growth and Microbiota Study	N/A
Completed	`NCT03422562` - Probiotics and Intestinal Microbiome in Preterm Infants	Phase 3
Recruiting	`NCT05695196` - Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.